Authors
, , , , , and
Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372: 793–795.
-
2. The White House. Fact sheet: President Obama's Precision Medicine Initiative. Available at: www.whitehouse.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative. Accessed Oct 13, 2015.
-
3. Daly MB, Pilarski R, Axilbund JE, et al. Genetic/familial high-risk assessment: breast and ovarian, version 1. 2014. J Natl Compr Canc Netw 2014; 12: 1326–1338.
-
4. Neveling K, Feenstra I, Gilissen C, et al. A post hoc comparison of the utility of Sanger sequencing and exome sequencing for the diagnosis of heterogeneous diseases. Hum Mutat 2013; 34: 1721–1726.
-
5. Hagemann IS, O'Neill PK, Erill I, et al. Diagnostic yield of targeted next-generation sequencing in various cancer types: an information-theoretic approach. Cancer Genet 2015; 208: 441–447.
-
6. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.
-
7. Röring M, Brummer T. Aberrant B-Raf signaling in human cancer—10 years from bench to bedside. Crit Rev Oncog 2012; 17: 97–121.
-
8. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364: 2305–2315.
-
9. Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012; 366: 2038–2040.
-
10. Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227–235.
-
11. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011–1019.
-
12. Von Hoff DD, Stephenson JJ, Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28: 4877–4883.
-
13. Barker AD, Sigman CC, Kelloff GJ, et al. I SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86: 97–100.
-
14. Prados MD, Byron SA, Tran NL, et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol 2015; 17: 1051–1063.
-
15. Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet [serial online]. 2014; 10: e1004135. Available at: journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1004135. Accessed Feb 13, 2014.
-
16. LoRusso PM, Boerner SA, Pilat MJ, et al. Pilot trial of selecting molecularly guided therapy for patients with non–V600 BRAF-mutant metastatic melanoma: experience of the SU2C/MRA Melanoma Dream Team. Mol Cancer Ther 2015; 14: 1962–1971.
-
17. Conley BA, Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. Semin Oncol 2014; 41: 297–299.
-
18. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011; 1: 44–53.
-
19. Saulnier Sholler GL, Bond JP, Bergendahl G, et al. Feasibility of implementing molecular guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. Cancer Med 2015; 4: 871–886.
-
20. Paoloni M, Davis S, Lana S, et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics [serial online]. 2009; 10;625. Available at: www.biomedcentral.com/1471-2164/10/625. Accessed Dec 23, 2009.
-
21. Paoloni M, Webb C, Mazcko C, et al. Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials. PLoS ONE [serial online]. 2014; 9: e90028. Available at: journals.plos.org/plosone/article?id=10.1371/journal.pone.0090028. Accessed Mar 1, 2014.
-
22. CDC. Leading causes of death. Available at: www.cdc.gov/nchs/fastats/leading-causes-of-death.htm. Accessed Sep 17, 2015.
-
23. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7: 201–204.
Advertisement
Precision medicine: an opportunity for a paradigm shift in veterinary medicine
K. C. Kent Lloyd
 DVM, PhD
K. C. Kent Lloyd
Department of Surgery, School of Medicine, University of California-Davis, Davis, CA 95616.
Search for other papers by K. C. Kent Lloyd in
Current site
Google Scholar
PubMed
Search for other papers by K. C. Kent Lloyd in
Current site
Google Scholar
PubMed
Chand Khanna
 DVM, PhD
Chand Khanna
Ethos Veterinary Health, 20 Cabot Rd, Woburn, MA 01801.
The Oncology Service, 4926 Wisconsin Ave NW, Washington, DC 20016.
Search for other papers by Chand Khanna in
Current site
Google Scholar
PubMed
The Oncology Service, 4926 Wisconsin Ave NW, Washington, DC 20016.
Search for other papers by Chand Khanna in
Current site
Google Scholar
PubMed
William Hendricks
 PhD
William Hendricks
Translational Genomics Research Institute, 445 N Fifth St, Phoenix, AZ 85004.
Search for other papers by William Hendricks in
Current site
Google Scholar
PubMed
Search for other papers by William Hendricks in
Current site
Google Scholar
PubMed
Jeffrey Trent
 PhD
Jeffrey Trent
Translational Genomics Research Institute, 445 N Fifth St, Phoenix, AZ 85004.
Search for other papers by Jeffrey Trent in
Current site
Google Scholar
PubMed
Search for other papers by Jeffrey Trent in
Current site
Google Scholar
PubMed
Michael Kotlikoff
 VMD, PhD
Michael Kotlikoff
Office of the Provost and College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.
Search for other papers by Michael Kotlikoff in
Current site
Google Scholar
PubMed
Search for other papers by Michael Kotlikoff in
Current site
Google Scholar
PubMed
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372: 793–795.
-
2. The White House. Fact sheet: President Obama's Precision Medicine Initiative. Available at: www.whitehouse.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative. Accessed Oct 13, 2015.
-
3. Daly MB, Pilarski R, Axilbund JE, et al. Genetic/familial high-risk assessment: breast and ovarian, version 1. 2014. J Natl Compr Canc Netw 2014; 12: 1326–1338.
-
4. Neveling K, Feenstra I, Gilissen C, et al. A post hoc comparison of the utility of Sanger sequencing and exome sequencing for the diagnosis of heterogeneous diseases. Hum Mutat 2013; 34: 1721–1726.
-
5. Hagemann IS, O'Neill PK, Erill I, et al. Diagnostic yield of targeted next-generation sequencing in various cancer types: an information-theoretic approach. Cancer Genet 2015; 208: 441–447.
-
6. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.
-
7. Röring M, Brummer T. Aberrant B-Raf signaling in human cancer—10 years from bench to bedside. Crit Rev Oncog 2012; 17: 97–121.
-
8. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364: 2305–2315.
-
9. Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012; 366: 2038–2040.
-
10. Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227–235.
-
11. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011–1019.
-
12. Von Hoff DD, Stephenson JJ, Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28: 4877–4883.
-
13. Barker AD, Sigman CC, Kelloff GJ, et al. I SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86: 97–100.
-
14. Prados MD, Byron SA, Tran NL, et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol 2015; 17: 1051–1063.
-
15. Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet [serial online]. 2014; 10: e1004135. Available at: journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1004135. Accessed Feb 13, 2014.
-
16. LoRusso PM, Boerner SA, Pilat MJ, et al. Pilot trial of selecting molecularly guided therapy for patients with non–V600 BRAF-mutant metastatic melanoma: experience of the SU2C/MRA Melanoma Dream Team. Mol Cancer Ther 2015; 14: 1962–1971.
-
17. Conley BA, Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. Semin Oncol 2014; 41: 297–299.
-
18. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011; 1: 44–53.
-
19. Saulnier Sholler GL, Bond JP, Bergendahl G, et al. Feasibility of implementing molecular guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. Cancer Med 2015; 4: 871–886.
-
20. Paoloni M, Davis S, Lana S, et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics [serial online]. 2009; 10;625. Available at: www.biomedcentral.com/1471-2164/10/625. Accessed Dec 23, 2009.
-
21. Paoloni M, Webb C, Mazcko C, et al. Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials. PLoS ONE [serial online]. 2014; 9: e90028. Available at: journals.plos.org/plosone/article?id=10.1371/journal.pone.0090028. Accessed Mar 1, 2014.
-
22. CDC. Leading causes of death. Available at: www.cdc.gov/nchs/fastats/leading-causes-of-death.htm. Accessed Sep 17, 2015.
-
23. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7: 201–204.
Advertisement
Powered by PubFactory